[Correspondence] How flaws in study design and lead-time bias could affect the interpretation of data – Authors' reply
Summary
We thank André Vis and Kim de Vries for their interest in our WOLVERINE study.1 We agree that, optimally, there will be well conducted phase III trials to inform the benefit of metastasis-directed therapy (MDT) for oligometastatic prostate cancer. However, these trials have yet to be reported, and in the interim, clinicians are left with an increasingly common clinical scenario that requires evidence-based direction…
We thank André Vis and Kim de Vries for their interest in our WOLVERINE study.1 We agree that, optimally, there will be well conducted phase III trials to inform the benefit of metastasis-directed therapy (MDT) for oligometastatic prostate cancer. However, these trials have yet to be reported, and in the interim, clinicians are left with an increasingly common clinical scenario that requires evidence-based direction. The highest-level data available are randomised phase 2 trials. However, heterogeneity exists between these trials given inherent differences and the timeframes over which they were run.